Impulse Oscillation to Evaluate Diagnostic Efficacy in Patients With Chronic Airway Disease
Primary Purpose
Chronic Airway Disease
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
impulse oscillation(IOS)
bronchial provocation test(BPT)
bronchial dilation test(BDT)
Sponsored by
About this trial
This is an interventional diagnostic trial for Chronic Airway Disease focused on measuring impulse oscillation, bronchial provocation test, bronchial dilation test, asthma, chronic obstructive pulmonary disease
Eligibility Criteria
Inclusion Criteria:
- 18-75 years old, no gender limit;
- The subject voluntarily cooperated with the research and signed an informed consent form;
Meet any of the following three criteria:
- Patients with asthma, the standard diagnosis of asthma complied with the GINA 2019; ② Patients with COPD, the standard diagnosis of COPD complied with GOLD 2019; ③ The subjects in the healthy control group had normal vital capacity (baseline FEV1≥80% of the predicted value, FEV1/FVC was greater than the Lower Limit of Normal, and with negative result of BPT or BDT).
Exclusion Criteria:
- History of other lung diseases, such as cystic fibrosis, bronchiolitis obliterans, tuberculosis, lung cancer, etc.;
- After taking corticosteroid therapy in the last 4 weeks, respiratory tract infection occurred within 8 weeks;
- A history of myocardial infarction and stroke in the past 3 months; a history of severe arrhythmia, severe cardiac insufficiency, and unstable angina in the past 4 weeks, etc.;
- In the past 4 weeks, severe hemoptysis and epileptic seizures require medication; severe hyperthyroidism;
- Pregnant women;
- Other researchers consider it inappropriate.
Sites / Locations
- Zhujiang Hospital of Southern Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
chronic airway disease group
Arm Description
Before the test, patients with FEV1/FVC≥0.7 are divided into the provocation test group, patients with FEV1/FVC <0.7 are divided into the dilation test group.
Outcomes
Primary Outcome Measures
The Value of the Change of IOS after BPT/BDT.
The value of respiratory reactance and resistance will be measured by Jaeger MasterScreen pulmonary function meter. And the main indicators that will be recorded are ΔZ5%、ΔR5%、ΔR20%、ΔR5-R20%、ΔR5-R20/R5%、ΔX5%、ΔAx% and ΔFres%. The receiver operating characteristic (Receiver Operating Characteristic, ROC) curve will be used to analyze the predictive value of IOS parameters for the positive results of BPT and BDT.
The Value of the Change of spirometry after BPT/BDT.
The value of spirometry will be performed with a spirometer (Jaeger, Hoechberg, Germany) in accordance with the specifications and performance criteria recommended in the American Thoracic Society (ATS)/European Respiratory Society (ERS) Standardization of Spirometry.And the main indicators that will be recorded are ΔFVC%、ΔFEV1%、ΔFEV1/FVC%、ΔMMEF%、ΔMEF75%、ΔMEF50% and ΔMEF25%.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04668027
Brief Title
Impulse Oscillation to Evaluate Diagnostic Efficacy in Patients With Chronic Airway Disease
Official Title
Evaluating the Efficacy of Impulse Oscillation Before and After Bronchial Provocation Test and Bronchial Dilation Test in Patients With Chronic Airway Disease
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Unknown status
Study Start Date
January 1, 2020 (Actual)
Primary Completion Date
June 1, 2022 (Anticipated)
Study Completion Date
June 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Zhujiang Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of the research is to explore the diagnostic efficacy of impulse oscillation (IOS) before and after bronchial provocation test (BPT) and bronchial dilation test (BDT) in chronic airway disease.
Detailed Description
The present study has the following objectives:
to explore the diagnostic value of IOS before and after BPT/BDT in chronic airway disease, to assess the diagnostic accuracy of IOS in chronic airway disease with special regard to its discriminating value between asthma and chronic obstructive pulmonary disease, to evaluate the characteristics of airway resistance after BPT/BDT, to evaluate the airway reversibility and hyperresponsiveness(AHR)in asthma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Airway Disease
Keywords
impulse oscillation, bronchial provocation test, bronchial dilation test, asthma, chronic obstructive pulmonary disease
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
172 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
chronic airway disease group
Arm Type
Experimental
Arm Description
Before the test, patients with FEV1/FVC≥0.7 are divided into the provocation test group, patients with FEV1/FVC <0.7 are divided into the dilation test group.
Intervention Type
Diagnostic Test
Intervention Name(s)
impulse oscillation(IOS)
Intervention Description
The patient is tested for the first IOS after the screening test, and performed the second IOS test immediately after the results of BPT or BDT. The patient takes seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calms breathing one minutes.
Intervention Type
Diagnostic Test
Intervention Name(s)
bronchial provocation test(BPT)
Intervention Description
Patient needs to cooperate with the inhalation of acetylcholine stimulants with low to high concentrations, and operates in accordance with the standard nebulized administration procedure. Measure FEV1 after each inhalation and take the high value. The interval between the inhalation of two adjacent doses is 5 minutes, until the FEV1 decrease value is ≥20% of the FEV1 base value or the highest inhalation concentration. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and performs exhalation and inhalation with the greatest strength and fastest speed. After the examination,the patient should inhale the bronchodilator salbutamol sulfate (400ug).
Intervention Type
Diagnostic Test
Intervention Name(s)
bronchial dilation test(BDT)
Intervention Description
The patient inhales the salbutamol sulfate (400ug). 15 minutes later, the pulmonary function tester is used for measurement. The patient needs to cooperate to ensure that the filter is as tight as possible to prevent air leakage, and to exhale and breathe with the greatest strength and fastest speed. Inhale.
Primary Outcome Measure Information:
Title
The Value of the Change of IOS after BPT/BDT.
Description
The value of respiratory reactance and resistance will be measured by Jaeger MasterScreen pulmonary function meter. And the main indicators that will be recorded are ΔZ5%、ΔR5%、ΔR20%、ΔR5-R20%、ΔR5-R20/R5%、ΔX5%、ΔAx% and ΔFres%. The receiver operating characteristic (Receiver Operating Characteristic, ROC) curve will be used to analyze the predictive value of IOS parameters for the positive results of BPT and BDT.
Time Frame
at least 4 weeks of treatment
Title
The Value of the Change of spirometry after BPT/BDT.
Description
The value of spirometry will be performed with a spirometer (Jaeger, Hoechberg, Germany) in accordance with the specifications and performance criteria recommended in the American Thoracic Society (ATS)/European Respiratory Society (ERS) Standardization of Spirometry.And the main indicators that will be recorded are ΔFVC%、ΔFEV1%、ΔFEV1/FVC%、ΔMMEF%、ΔMEF75%、ΔMEF50% and ΔMEF25%.
Time Frame
at least 4 weeks of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
18-75 years old, no gender limit;
The subject voluntarily cooperated with the research and signed an informed consent form;
Meet any of the following three criteria:
Patients with asthma, the standard diagnosis of asthma complied with the GINA 2019; ② Patients with COPD, the standard diagnosis of COPD complied with GOLD 2019; ③ The subjects in the healthy control group had normal vital capacity (baseline FEV1≥80% of the predicted value, FEV1/FVC was greater than the Lower Limit of Normal, and with negative result of BPT or BDT).
Exclusion Criteria:
History of other lung diseases, such as cystic fibrosis, bronchiolitis obliterans, tuberculosis, lung cancer, etc.;
After taking corticosteroid therapy in the last 4 weeks, respiratory tract infection occurred within 8 weeks;
A history of myocardial infarction and stroke in the past 3 months; a history of severe arrhythmia, severe cardiac insufficiency, and unstable angina in the past 4 weeks, etc.;
In the past 4 weeks, severe hemoptysis and epileptic seizures require medication; severe hyperthyroidism;
Pregnant women;
Other researchers consider it inappropriate.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Huapeng Yu
Phone
+86 020-61643888
Email
huapengyu@aliyun.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Huapeng Yu
Organizational Affiliation
Southern Medical University, China
Official's Role
Principal Investigator
Facility Information:
Facility Name
Zhujiang Hospital of Southern Medical University
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huapeng Yu
Phone
+86 020-61643888
Email
huapengyu@aliyun.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Impulse Oscillation to Evaluate Diagnostic Efficacy in Patients With Chronic Airway Disease
We'll reach out to this number within 24 hrs